A Phase 1 interventional study of MK-8266 and Placebo in Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-11-05.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Hypertension by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Hypertension · Merck & Co., Inc.
Among the 33 studies in Hypertension by Merck & Co., Inc, this one is the 31st largest by enrollment of the 32 interventional ones that give a count, is one of 6 that started in 2010, is one of 17 in phase 1, and was the 22nd registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →None of the 33 studies in Hypertension by Merck & Co., Inc is open now. The open studies under Hypertension, anywhere →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 65 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 1990; this study’s year is marked. 6 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 84 across the 32 interventional studies, 450 across the 1 observational. Of the 33 that completed or were terminated, 27 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 33 studies in Hypertension by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled study. The hypothesis for this study is that single oral doses of MK-8266 selected for this study are sufficiently safe and well tolerated by elderly male and elderly female participants with hypertension to permit continued clinical investigation.
Two panels, each consisting of eight participants (8 elderly males with mild to moderate hypertension in Panel A and 8 elderly females with mild to moderate hypertension in Panel B) will be randomized to receive either MK-8266 or matching placebo in a 3:1 ratio. Participants will receive single doses of MK-8266 or matching placebo in three treatment periods (Periods 1 through 3). In both Panel A and Panel B, doses will escalate in a rising, fixed sequence. In Period 1 (0.3 mg), Period 2 (0.6 mg), and Period 3 (0.7 mg and then 0.3 mg 10 hours later) once daily doses of MK-8266 or matching placebo will be administered.
All participants will receive at least 2 doses of MK-8266. Participants completing placebo treatment in Period 1 will flow to the MK-8266 arm in the next period, with 2 participants from the MK-8266 arm receiving placebo in the next period.
Blood samples will be obtained pre-dose and at selected time points up to 48 hours post-dose for determination of MK-8266 plasma concentrations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MK-8266 single dose 0.3 mg
Drug: MK-8266
MK-8266 single dose 0.6 mg
Drug: MK-8266
MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours
Drug: MK-8266
Placebo to MK-8266 single dose
Drug: Placebo
MK-8266 single dose 0.3 mg
Drug: MK-8266
MK-8266 single dose 0.6 mg
Drug: MK-8266
MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours
Drug: MK-8266
Placebo to MK-8266 single dose
Drug: Placebo
Oral capsules, 0.1 mg potency
Oral placebo capsules to match MK-8266 capsules
Number of Participants With Adverse Events (AEs)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to 48 days
Number of Participants With Abnormal Laboratory Hematology Values Reported as an AE
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory hematology value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory hematology value.
Time frame: Up to 48 days
Number of Participants With Abnormal Laboratory Chemistry Values Reported as an AE
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory chemistry value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory chemistry value.
Time frame: Up to 48 days
Number of Participants With Abnormal Laboratory Urinalysis Values Reported as an AE
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory urinalysis value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory urinalysis value.
Time frame: Up to 37 days
Change From Baseline in Systolic Blood Pressure (SBP)
Participants rested for at least 10 minutes prior to having vital sign measurements obtained.
Time frame: Baseline and 0 to 8 hours postdose
Change From Baseline in Heart Rate
Participants rested for at least 10 minutes prior to having vital sign measurements obtained. Heart rate measurements were obtained in the semirecumbent position and 3 sets of measurements were obtained approximately 1 minute apart.
Time frame: Baseline and 0 to 8 hours postdose
Number of Participants With Abnormal Electrocardiograms (ECG) Reported as an AE
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. An abnormal ECG value was any AE reported under the System Organ Classes of Investigations or Cardiac that was related to an abnormal ECG value.
Time frame: Up to 48 days
MK-8266 Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. (AUC\[0-inf\]) is a measure of the mean concentration levels of drug in the plasma after the dose.
Time frame: Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.
MK-8266 PK Parameter Observed Maximum (Peak) Plasma Concentration (Cmax)
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.
Time frame: Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.
MK-8266 PK Parameter Observed Time to Reach Cmax (Tmax)
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. Nominal instead of actual times are presented.
Time frame: Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.
MK-8266 PK Parameter Apparent Half-Life (t1/2)
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. t1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. Results are presented for the Harmonic Mean ± Pseudo standard deviation.
Time frame: Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.
The Time Weighted Average Systolic Blood Pressure (SBP) Evaluated Over 8 Hours Post Dose (TWA[0-8hrs]) Following a Single Oral Dose of MK-8266.
Participants rested for at least 10 minutes prior to having vital sign measurements obtained. Single dose effects on central SBP were estimated as a time-weighted average over the 8-hour post single dose observation period.
Time frame: Up to 8 hours post dose in each dosing period (Up to 8 hours)
| Milestone | Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 1 | Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 2 | Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 3 | Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 4 | Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 1 | Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 2 | Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 3 | Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 4 |
|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 1 | Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 2 | Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 3 | Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 4 | Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 1 | Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 2 | Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 3 | Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 4 |
|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 1 | Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 2 | Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 3 | Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 4 | Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 1 | Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 2 | Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 3 | Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 4 |
|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Participants | Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN) | Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN) | Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN) | Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 4 | 4 | 3 | 1 | 5 | 4 | 4 | 4 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory hematology value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory hematology value.
| Participants | Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN) | Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN) | Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN) | Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Abnormal Laboratory Hematology Values Reported as an AE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory chemistry value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory chemistry value.
| Participants | Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN) | Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN) | Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN) | Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Abnormal Laboratory Chemistry Values Reported as an AE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory urinalysis value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory urinalysis value.
| Participants | Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN) | Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN) | Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN) | Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Abnormal Laboratory Urinalysis Values Reported as an AE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Participants rested for at least 10 minutes prior to having vital sign measurements obtained.
| Millimeters of mercury | Panel A MK-8266 0.3 mg (Elderly Males With Mild/Mod. HTN) | Panel A MK-8266 0.6 mg (Elderly Males With Mild/Mod. HTN) | Panel A MK-8266 0.7 /0.3 (Elderly Males With Mild/Mod. HTN) | Panel A Placebo to MK-8266 (Elderly Males Mild/Moderate HTN) | Panel B MK-8266 0.3 mg (Elderly Females With Mild/Mod. HTN) | Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN) | Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) |
|---|---|---|---|---|---|---|---|---|
| Baseline | 148.3 ± 8.87 | 137.2 ± 19.09 | 134.0 ± 12.96 | 132.7 ± 10.93 | 141.7 ± 13.38 | 139.5 ± 11.10 | 137.7 ± 7.76 | 142.0 ± 18.10 |
| Change from Baseline | -0.71 ± 3.85 | -0.79 ± 7.44 | -1.13 ± 4.13 | 0.54 ± 4.83 | -0.33 ± 10.01 | -4.16 ± 10.25 | -2.28 ± 5.87 | 5.91 ± 9.00 |
Participants rested for at least 10 minutes prior to having vital sign measurements obtained. Heart rate measurements were obtained in the semirecumbent position and 3 sets of measurements were obtained approximately 1 minute apart.
| Beats per minute | Panel A MK-8266 0.3 mg (Elderly Males With Mild/Mod. HTN) | Panel A MK-8266 0.6 mg (Elderly Males With Mild/Mod. HTN) | Panel A MK-8266 0.7 /0.3 (Elderly Males With Mild/Mod. HTN) | Panel A Placebo to MK-8266 (Elderly Males Mild/Moderate HTN) | Panel B MK-8266 0.3 mg (Elderly Females With Mild/Mod. HTN) | Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN) | Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) |
|---|---|---|---|---|---|---|---|---|
| Baseline | 68.83 ± 9.24 | 67.83 ± 10.53 | 58.33 ± 5.50 | 69.00 ± 8.37 | 65.33 ± 5.32 | 65.00 ± 5.97 | 61.33 ± 4.23 | 63.83 ± 5.64 |
| Change from Baseline | 0.58 ± 6.12 | 4.23 ± 4.78 | 7.90 ± 4.89 | 0.11 ± 7.85 | 2.40 ± 2.37 | 5.51 ± 3.27 | 6.65 ± 3.33 | 1.25 ± 3.57 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. An abnormal ECG value was any AE reported under the System Organ Classes of Investigations or Cardiac that was related to an abnormal ECG value.
| Participants | Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN) | Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN) | Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN) | Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Abnormal Electrocardiograms (ECG) Reported as an AE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. (AUC\[0-inf\]) is a measure of the mean concentration levels of drug in the plasma after the dose.
| nM•hr | Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN) | Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN) | Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN) | Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) |
|---|---|---|---|---|---|---|---|---|
| MK-8266 Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf]) | — | 208 ± 81.5 | 314 ± 108 | — | — | 247 ± 66.8 | 449 ± 130 | — |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.
| ng/mL | Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN) | Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN) | Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN) | Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) |
|---|---|---|---|---|---|---|---|---|
| MK-8266 PK Parameter Observed Maximum (Peak) Plasma Concentration (Cmax) | 7.76 ± 2.25 | 14.1 ± 3.45 | 16.2 ± 4.13 | — | 7.84 ± 1.80 | 17.8 ± 2.52 | 19.5 ± 2.61 | — |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. Nominal instead of actual times are presented.
| Hours | Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN) | Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN) | Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN) | Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) |
|---|---|---|---|---|---|---|---|---|
| MK-8266 PK Parameter Observed Time to Reach Cmax (Tmax) | 2.0 (1.5 to 4.0) | 2.0 (1.5 to 3.0) | 2.0 (2.0 to 3.0) | — | 4.0 (2.0 to 6.0) | 3.5 (2.0 to 4.0) | 4.0 (3.0 to 12) | — |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. t1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. Results are presented for the Harmonic Mean ± Pseudo standard deviation.
| Hours | Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN) | Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN) | Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN) | Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) |
|---|---|---|---|---|---|---|---|---|
| MK-8266 PK Parameter Apparent Half-Life (t1/2) | — | 12.7 ± 4.8 | 14.3 ± 3.8 | — | — | 13.6 ± 4.5 | 15.4 ± 3.4 | — |
Participants rested for at least 10 minutes prior to having vital sign measurements obtained. Single dose effects on central SBP were estimated as a time-weighted average over the 8-hour post single dose observation period.
| millimeters of mercury | Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN) | Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN) | Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN) | Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) |
|---|---|---|---|---|---|---|---|---|
| The Time Weighted Average Systolic Blood Pressure (SBP) Evaluated Over 8 Hours Post Dose (TWA[0-8hrs]) Following a Single Oral Dose of MK-8266. | 146.4 ± 11.73 | 134.2 ± 12.96 | 132.7 ± 12.34 | 136.8 ± 8.61 | 142.4 ± 13.19 | 135.0 ± 8.22 | 136.0 ± 6.82 | 146.6 ± 12.54 |
Collected over Up to 48 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Event | Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN) | Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN) | Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN) | Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) | Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN) | Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) |
|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/6 | 2/6 | 1/6 | 0/6 | 1/6 | 3/6 | 1/6 | 2/6 |
| NasopharyngitisInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 2/6 | 0/6 |
| Blood pressure systolic increasedInvestigations | 2/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 1/6 | 1/6 |
| Skin irritationSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 0/6 | 0/6 | 2/6 | 0/6 | 0/6 | 0/6 |
| Abdominal discomfortGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/6 | 1/6 | 0/6 | 1/6 | 1/6 | 1/6 | 0/6 |
| Faeces hardGastrointestinal disorders | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| NauseaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 |
| VomitingGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 1/6 |
Baseline characteristics for all participants receiving study treatment. Participants are grouped according to either Panel A or Panel B (i.e. males or females with mild/moderate hypertension).
| Age, Continuous(Years) | Panel A (Elderly Males, Mild/Moderate Hypertension) | Panel B (Elderly Females, Mild/Moderate Hypertension) | Total |
|---|---|---|---|
| Mean | 68.0 ± 2.8 | 68.9 ± 2.8 | 68.4 ± 2.7 |
| Sex: Female, Male(Participants) | Panel A (Elderly Males, Mild/Moderate Hypertension) | Panel B (Elderly Females, Mild/Moderate Hypertension) | Total |
|---|---|---|---|
| Female | 0 | 8 | 8 |
| Male | 8 | 0 | 8 |
No study locations are listed for this record.
Ran from Nov 2010 to primary completion in Feb 2011, 3 months.
Results were first posted in Nov 2018, 7 years 9 months after primary completion.
Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 3 months is above that.
Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-8266